Compare CCO & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | ORIC |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2005 | 2020 |
| Metric | CCO | ORIC |
|---|---|---|
| Price | $2.40 | $12.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $2.43 | ★ $21.43 |
| AVG Volume (30 Days) | ★ 4.2M | 1.3M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 23.24% | N/A |
| EPS Growth | ★ 110.81 | 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,604,140,000.00 | N/A |
| Revenue This Year | $7.33 | N/A |
| Revenue Next Year | $2.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.57 | N/A |
| 52 Week Low | $1.27 | $7.23 |
| 52 Week High | $2.44 | $14.68 |
| Indicator | CCO | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 56.08 | 42.29 |
| Support Level | $2.37 | $11.86 |
| Resistance Level | $2.41 | $12.59 |
| Average True Range (ATR) | 0.02 | 0.73 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 81.25 | 20.38 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.